cas 2241134-68-7|| where to buy 3-(2,5-dichloropyrimidin-4-yl)-6-methyl-1H-indole

Nom du produit:3-(2,5-dichloropyrimidin-4-yl)-6-methyl-1H-indole

IUPAC Name:3-(2,5-dichloropyrimidin-4-yl)-6-methyl-1H-indole

Unité d'emballage	Stock disponible	Prix($)	Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2241134-68-7 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:2241134-68-7; Formule moléculaire:C13H9Cl2N3; Point de fusion:-; Code SMILES:CC1=CC2=C(C=C1)C(=CN2)C1=C(Cl)C=NC(Cl)=N1; Densité:

: Numéro de catalogue:CM1075711; Poids moléculaire:278.14; Point d'ébullition:; N° Mdl:; Stockage:

: Indoles; Indole is a compound of pyrrole and benzene in parallel, also known as benzopyrrole. There are two combinations of pyrrole and benzene, called indole and isoindole, respectively. Many derivatives of indole have physiological and pharmacological activities, and can synthesize vasodilators, antihistamines, antipyretic analgesics, etc. in medicine, so indole is also a very important heterocyclic compound.; indole company; As a indole company,we sincerely welcome the new and old friends from home and abroad to synergize with our company and share the benefits and opportunities.

: Tuspetinib; Venetoclax (VEN) combined with a hypomethylating agent (HMA) has proven effective for treating acute myeloid leukemia (AML) patients who are ineligible for intensive chemotherapy. However, this combination therapy still faces issues such as low response rates, limited survival, and potential resistance to VEN.
Aptose’s Tuspetinib (TUS) is a multi-kinase inhibitor selectively targeting SYK, RSK, FLT3 , JAK1/2, KIT, which drive proliferation in AML. The addition of Tuspetinib into VEN and HMA therapy improves medical efficacy and and may help prevent resistance to both agents. TUS+VEN+HMA triplet protocol in frontline therapy for newly diagnosed (ND) AML is currently being tested in a global phase 1/2 trial.